

LOINC component - Mapping of LOINC component for Susceptibility LOINC terms

Farzaneh Ashrafi

Owner

2582 View 8 Comment [IN DISCUSSION](#) Comments enabled In the category: [UNDEFINED](#)

Mapping of LOINC Part components used in susceptibility LOINC terms, specifically the ones that contain more than one antibiotics:

18865-6	Ampicillin+Sulbactam	Susc	Pt	Isolate	OrdQn	
20374-5	Ampicillin+Sulbactam	Susc	Pt	Isolate	OrdQn	Method for Slow-growing mycobacteria
43251	Ampicillin+Sulbactam	Susc	Pt	Isolate	Qn	MLC
11749	Ampicillin+Sulbactam	Susc	Pt	Isolate	OrdQn	MIC
12055	Ampicillin+Sulbactam	Susc	Pt	Isolate	OrdQn	Agar diffusion
1855616	Ampicillin+Sulbactam	Susc	Pt	Isolate	OrdQn	Gradient strip

And the ones that contain strength:

48177-0	Streptomycin 1.0 ug/mL	Susc	Pt	Isolate	OrdQn	Method for Slow-growing mycobacteria
25206-4	Streptomycin 10.0 ug/mL	Susc	Pt	Isolate	OrdQn	Method for Slow-growing mycobacteria
25205-6	Streptomycin 2.0 ug/mL	Susc	Pt	Isolate	OrdQn	Method for Slow-growing mycobacteria
46719-1	Streptomycin 4.0 ug/mL	Susc	Pt	Isolate	OrdQn	Method for Slow-growing mycobacteria
25185-0	Streptomycin 6.0 ug/mL	Susc	Pt	Isolate	OrdQn	Method for Slow-growing mycobacteria

This issue needs to be considered in association with [CTP Project - Elaboration document on Susceptibility](#):

The modelling design (using the deposition observable / flattened format) is as follows:

*"Observable entity" and
'property type' some 'Susceptibility' and
'towards' some <LOINC.component> and
'technique' some <LOINC.method> and
'scale' some <LOINC.scale>
'time aspect' some 'Single point in time'
'inheres in' some 'Microorganism' and
'Direct site = 119303007 | Microbial isolate specimen (specimen) |"*

In mapping 'towards' some <LOINC.component>:

1) We have mapped the LOINC parts containing one antibiotic to the equivalent substance

*LP28719-0 1 Gatifloxacin (Mapped to: 116349004 Gatifloxacin (substance))
LP33354-9 1 Daptomycin (Mapped to: 406439009 Daptomycin (substance))*

2) For the ones containing multiple substances, see [the latest associated guideline for compound substances](#):

Combined substances added to the Substance hierarchy must meet the following criteria:

- The physiologic or biologic action of the combination must be enhanced or synergistic
- Combinations that do not have an enhanced or synergistic effect (e.g. combinations created for convenience) are out of scope.

Contributors (4)

- [Daniel Karlsson](#)
Number of accepted comment 0
Number of comment 4
- [Farzaneh Ashrafi](#)
Number of accepted comment 0
Number of comment 1
- [Jeremy Rogers](#)
Number of accepted comment 0
Number of comment 1
- 
[Xavier GANSEL](#)
Number of accepted comment 0
Number of comment 2

File	Modified
PDF File Supplementary_Inse rt_-_16248_-_ _B_-_en_-_ _Etest_-_ _Product_Sup plement_MBL_ IP-IPI.pdf	2018- Mar-27 by Daniel Karlsson
PDF File Supplementary_Inse rts_-_15204_-_ _E_-_en_-_ _Etest_-_ _Enclosure_16 29298.pdf	2018- Mar-27 by Daniel Karlsson
PDF File 001_-_ _LOINC_Code s_-_ _Etest_Range _-_ _Release_V1. 0_-_2017-10. pdf	2018- Mar-27 by Daniel Karlsson
PDF File Package_Insert_US _-_15203_-_ _E_-_en_-_ _Etest_-_ _AST594594. pdf	2018- Mar-27 by Daniel Karlsson

[Download All](#)

Examples of combined substances that are in scope include: Ampicillin + sulbactam Piperacillin + tazobactam

Examples:

LP15937-3 1 Ampicillin+Sulbactam (Mapped to: 703744001 | Ampicillin and sulbactam (substance) |. A product concept also exist: 398786001 Product containing ampicillin and sulbactam (medicinal product))

LP29104-4 1 Quinupristin+Dalfopristin (No substance concept created yet. Product concept: 324352008 Product containing dalfopristin and quinupristin (medicinal product))

3) LOINC terms with an antibiotic component with strength specified:

*LP229026-2 1 COMPONENT Moxifloxacin 0.5 ug/mL
LP229027-0 1 COMPONENT Moxifloxacin 1.0 ug/mL*